Physician profile
Carl Johnson
NPI 1023018561
$5,757.26
in general payments reported to CMS, 2019-2025
42 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $151 · 2021: $713 · 2022: $909 · 2023: $1,102 · 2024: $1,185 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,386.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $693.25 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $659.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $522.69 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $456.84 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $384.53 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $380.90 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $355.12 | 2019-2025 | |
| Amarin Pharma, INC. | $299.25 | 2019-2022 | |
| Dexcom, INC. | $294.50 | 2022-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $192.25 | 2019-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $156.58 | 2022-2023 | |
| Shield Therapeutics INC | $126.52 | 2024-2025 | |
| Medtronic, INC. | $124.05 | 2023-2025 | Minimed 780g |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.04 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $115.22 | 2021-2024 | Veozah |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.